scholarly journals Erratum to: Beta-Blockers and Ivabradine in Chronic Heart Failure: From Clinical Trials to Clinical Practice

2014 ◽  
Vol 14 (4) ◽  
pp. 333-333
Author(s):  
Antonino Di Franco ◽  
Filippo M. Sarullo ◽  
Ylenia Salerno ◽  
Stefano Figliozzi ◽  
Rossella Parrinello ◽  
...  
Keyword(s):  
Heart Failure ◽  
Clinical Trials ◽  
Clinical Practice ◽  
Chronic Heart Failure ◽  
Beta Blockers

Beta-Blockers and Ivabradine in Chronic Heart Failure: From Clinical Trials to Clinical Practice

2013 ◽  
Vol 14 (2) ◽  
pp. 101-110 ◽  
Author(s):  
Antonino Di Franco ◽  
Filippo M. Sarullo ◽  
Ylenia Salerno ◽  
Stefano Figliozzi ◽  
Rossella Parrinello ◽  
...  
Keyword(s):  
Heart Failure ◽  
Clinical Trials ◽  
Clinical Practice ◽  
Chronic Heart Failure ◽  
Beta Blockers

scholarly journals The use of beta-blockers in patients with chronic obstructive pulmonary disease and chronic heart failure in real clinical practice

2021 ◽  
Vol 2 (1) ◽  
pp. 70-75
Author(s):  
N. A. Karoli ◽  
A. V. Borodkin ◽  
A. P. Rebrov
Keyword(s):  
Heart Failure ◽  
Chronic Obstructive Pulmonary Disease ◽  
Clinical Practice ◽  
Chronic Heart Failure ◽  
Pulmonary Disease ◽  
Beta Blockers ◽  
Dose Titration ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Real Clinical Practice

Objective: to reveal the features of the use of beta-blockers (BB) in patients with chronic obstructive pulmonary disease (COPD) and chronic heart failure (CHF) in real clinical practice.Materials and methods: the study included 90 patients with COPD and CHF, and 41 patients with CHF of ischemic genesis without COPD.Results: patients with COPD and CHF were significantly less likely to receive beta-blockers (BB) compared with patients with CHF. Of the BB patients with COPD and CHF were primarily prescribed bisoprolol, its average dose was 4.45 ± 1.74 mg per day. Patients with COPD and CHF of ischemic genesis of BB were prescribed significantly more often, and diuretics were significantly less likely than patients with COPD and CHF without myocardial infarction. Patients with COPD and CHF with ejection fraction of the left ventricle (LVEF) more than 40% were less likely to take BB than patients with COPD and CHF with reduced EF (less than 40%), and also less frequently, than patients with CHF without COPD with LVEF more than 40%.Conclusion: BB, as first-line drugs in the treatment of CHF, was prescribed on an outpatient basis only to half of patients with COPD and CHF, which does not comply with current guidelines for the management of patients with comorbid conditions. In the vast majority of cases, highly selective BB were prescribed. It should be noted low doses of BB, the absence of dose titration, which does not correspond to modern recommendations for the treatment of chronic heart failure.

scholarly journals SUPPORTING DEVICES IN THE TREATMENT OF CHRONIC HEART FAILURE IN ELDERLY AND OLD PATIENTS

2020 ◽  
Vol 2 (3) ◽  
pp. 40-57
Author(s):  
Gennadiy Hubulava ◽  
Kirill L. Kozlov ◽  
Andrey N. Bogomolov ◽  
Aleksey Volkov ◽  
Viktor N. Fedorets ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Clinical Practice ◽  
Chronic Heart Failure ◽  
Severe Heart Failure ◽  
Circulatory Support ◽  
Old Patients ◽  
Western Countries ◽  
Surgical Methods

Chronic heart failure (CHF) is a widespread disease associated with high rates of disability and mortality, as well as a decrease in the quality of life. Moreover, the vast majority of patients are elderly and senile. Modern surgical methods of treating heart failure are able to increase the duration and quality of life of such patients, however, the need far exceeds the volume of this care, and some highly effective methods common in Western countries are still not used in Russian clinical practice. Elderly age is a risk factor for the development of senile asthenia (frailty) and concomitant pathology. Large abdominal surgery is often contraindicated for patients with signs of senile asthenia, and the method of choice in patients with severe heart failure is the implantation of devices for long-term mechanical circulatory support (LT-MCS). After implantation of LT-MCS, a regression of signs of senile asthenia may be observed. The topic of an integrated approach to non-drug treatment of heart failure in elderly and senile patients in Russia has not been studied enough. In particular, the implantation of LT-MCS is not used in Russian clinical practice, while in many Western countries for many years it has been the main and most effective treatment for severe heart failure. Systematization of the available up-to-date information on this topic could help increase the duration and quality of life of patients with severe heart failure.

scholarly journals Clinical Characteristics of De Novo Heart Failure and Acute Decompensated Chronic Heart Failure: Are They Distinctive Phenotypes That Contribute to Different Outcomes?

2021 ◽  
Vol 7 ◽  
Author(s):  
Wilson Matthew Raffaello ◽  
Joshua Henrina ◽  
Ian Huang ◽  
Michael Anthonius Lim ◽  
Leonardo Paskah Suciadi ◽  
...  
Keyword(s):  
Heart Failure ◽  
Clinical Trials ◽  
Chronic Heart Failure ◽  
Poor Prognosis ◽  
Clinical Characteristics ◽  
De Novo ◽  
Heart Failure Patients ◽  
Treat Heart Failure ◽  
Patients With Heart Failure ◽  
New Strategies

Heart failure is currently one of the leading causes of morbidity and mortality. Patients with heart failure often present with acute symptoms and may have a poor prognosis. Recent evidence shows differences in clinical characteristics and outcomes between de novo heart failure (DNHF) and acute decompensated chronic heart failure (ADCHF). Based on a better understanding of the distinct pathophysiology of these two conditions, new strategies may be considered to treat heart failure patients and improve outcomes. In this review, the authors elaborate distinctions regarding the clinical characteristics and outcomes of DNHF and ADCHF and their respective pathophysiology. Future clinical trials of therapies should address the potentially different phenotypes between DNHF and ADCHF if meaningful discoveries are to be made.

scholarly journals The Impact of Treatment with Beta-Blockers upon Mortality in Chronic Heart Failure Patients

2016 ◽  
Vol 4 (1) ◽  
pp. 94-97 ◽  
Author(s):  
Borjanka Taneva ◽  
Daniela Caparoska
Keyword(s):  
Heart Failure ◽  
Relative Risk ◽  
Chronic Heart Failure ◽  
Beta Blocker ◽  
Cardiovascular Mortality ◽  
Conventional Therapy ◽  
Therapy Group ◽  
Beta Blockers ◽  
Control Group ◽  
Heart Failure Patients

BACKGROUND: Besides the conventional therapy for heart failure, the diuretics, cardiac glycosides and ACE-inhibitors, current pharmacotherapy includes beta-blockers, mainly because of their pathophysiological mechanisms upon heart remodeling.AIM: The study objective was to assess the cardiovascular mortality in the beta-blocker therapy group and to correlate it with the mortality in the control group as well as to correlate the combined outcome of death and/or hospitalization for cardiovascular reason between the two groups.               MATERIALS AND METHODS: The study included 113 chronic heart failure patients followed up for a period of 18 months. The therapy group received conventional therapy plus the target dose of beta blockers, and the control group received the conventional therapy only. The therapy group was divided in three separate subgroups in terms of the type of beta-blocker (Metoprolol subgroup, Bisoprolol and Carvedilol subgroup). To compare the mortality and the combined outcome, the RRR (relative risk reduction) and NNT (number needed to treat) were used, as well as the survival analysis by Kaplan-Meier.RESULTS: The results showed the following: in regards of the cardiovascular mortality, the relative risk for death in the therapy group was 34%, which, though statistically not significant, is of great clinical significance. In regards of the combined outcome (death and/or number of hospitalizations) the results showed a RRR of 40% in the therapy group compared to the control group, which is statistically highly significant.CONCLUSION: The study confirmed that patients with stable chronic heart failure, treated with optimal doses of beta-blockers, show a significant reduction of the risk from death as well as combined outcome (death and/or number of hospitalizations).

Sign in / Sign up

Export Citation Format

Share Document